Imagion Biosystems has released Change of Director’s Interest Notices for David Ludvigson, Mark Van Asten, and Robert Proulx.
Read the Change in Director’s Interest Notices:
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce